FMP
CollPlant Biotechnologies Ltd.
CLGN
NASDAQ
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
4.03 USD
-0.14 (-3.47%)
Zacks Investment Research
Aug 21, 2024
CollPlant (CLGN) and Stratasys announce the initiation of a pre-clinical study to focus on the ability of implants to grow natural breast tissue and completely degrade over time.
PRNewsWire
Aug 6, 2024
Conference call to be held on Tuesday, August 20, 2024, at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial statements for the second quarter of 2024 on Tuesday, August 20, 2024, before the opening of the U.S. ...
Zacks Investment Research
May 10, 2024
CollPlant Biotechnologies (CLGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Seeking Alpha
Apr 4, 2024
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2023 Earnings Conference Call April 4, 2024 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.
PRNewsWire
Jan 8, 2024
REHOVOT, Israel , Jan. 8, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that Mr. Yehiel Tal, the Company's CEO, will participate in the Octane Aesthetic Tech Forum, being held on January 25-26, 2024 in Newport Beach, CA.
Seeking Alpha
Nov 29, 2023
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q3 2023 Earnings Conference Call November 29, 2023 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings.
PRNewsWire
Sep 5, 2023
REHOVOT, Israel , Sept. 5, 2023 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will participate at the H.C Wainwright Annual Growth Conference, to be held from September 11-13, 2023 in New York, NY.
Seeking Alpha
Aug 24, 2023
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q2 2023 Earnings Conference Call August 24, 2023 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.
PRNewsWire
Aug 9, 2023
- Conference call to be held on Thursday, August 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel, Aug. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the second quarter of 2023 on Thursday, August 24, 2023, before the market open.
Seeking Alpha
Mar 29, 2023
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2022 Earnings Conference Call March 29, 2023 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - Chief Executive Officer Eran Rotem - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Swayampakula Ramakanth - H.C.